Format

Send to

Choose Destination
Joint Bone Spine. 2016 Jan;83(1):31-6. doi: 10.1016/j.jbspin.2015.05.002. Epub 2015 Jul 7.

Does platelet-rich plasma have a role in the treatment of osteoarthritis?

Author information

1
CIC-P Inserm 803, plateforme d'investigation technologique, Dijon University Hospital, 21000 Dijon, France; Département de rhumatologie, hôpital universitaire de Dijon, Bocage Central, 14, rue Paul-Gaffarel, 21079 Dijon, France. Electronic address: paul.ornetti@chu-dijon.fr.
2
Département de chirurgie orthopédique, groupe Maussins, 75019 Paris, France; UPMC Paris VI, Inserm UMR-S938, université de la Sorbonne, 75012 Paris, France.
3
UPMC Paris VI, Inserm UMR-S938, université de la Sorbonne, 75012 Paris, France; Département de rhumatologie, hôpital Saint-Antoine, 75012 Paris, France.
4
Département de rhumatologie, université Paris VII, hôpital Lariboisière, 75010 Paris, France.
5
Département de rhumatologie, université Paris XII, hôpital Henri-Mondor, 94000 Créteil, France.

Abstract

Platelet-rich plasma (PRP) has been generating considerable attention as an intra-articular treatment to alleviate the symptoms of osteoarthritis. Activated platelets release a host of soluble mediators such as growth factors and cytokines, thereby inducing complex interactions that vary across tissues within the joint. In vivo, PRP may promote chondrocyte proliferation and differentiation. The available data are somewhat conflicting regarding potential effects on synovial cells and angiogenesis modulation. PRP probably exerts an early anti-inflammatory effect, which may be chiefly mediated by inhibition of the NF-κB pathway, a hypothesis that requires confirmation by proof-of-concept studies. It is far too early to draw conclusions about the efficacy of PRP as a treatment for hip osteoarthritis. The only randomized trial versus hyaluronic acid showed no significant difference in effects, and no placebo-controlled trials are available. Most of the randomized trials in knee osteoarthritis support a slightly greater effect in alleviating the symptoms compared to visco-supplementation, most notably at the early stages of the disease, although only medium-term data are available. Many uncertainties remain, however, regarding the best administration regimen. Serious adverse effects, including infections and allergies, seem rare, although post-injection pain is more common than with other intra-articular treatments for osteoarthritis.

KEYWORDS:

Hip; Knee; Osteoarthritis; Platelet-rich plasma; Review; Treatment

PMID:
26162636
DOI:
10.1016/j.jbspin.2015.05.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center